In vitro or ex vivo method for determining effect of biological sample on biological model using large scale neural activity

By recording neuronal functional activity using multi-compartment microfluidic devices and biosensors, and analyzing the data, rapid and reliable diagnosis of neurological diseases can be achieved. This solves the problems of low sensitivity and difficulty in early diagnosis in traditional methods, and improves the specificity and sensitivity of diagnosis.

CN118974744APending Publication Date: 2024-11-15NETLI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032714.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-09
Filing Date
2023-02-09
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing diagnostic methods for neurological diseases lack sensitive, rapid, and repeatable testing methods. Traditional biosensors have low sensitivity, making it difficult to detect subtle changes in cognitive function and unable to make early differential diagnoses.

Method used

A biosensor employing a multi-compartment microfluidic device records neuronal functional activity by culturing neurons and non-neurons, analyzes the functional activity data to determine the neural network state, utilizes a bio-interface to achieve neural connections, and combines graph theory and algorithm systems for data transformation and comparison to achieve rapid and reliable diagnosis.

Benefits of technology

It enables rapid and low-cost differential diagnosis of neurological diseases and neurological disorders, improves specificity and sensitivity, allows for early detection of diseases, and is suitable for personalized treatment and prevention of complications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974744A_ABST
    Figure CN118974744A_ABST
Patent Text Reader

Abstract

The present invention relates to an in vitro or ex vivo method for determining the effect of a biological sample on a biological interface, the method comprising in particular implementing a biosusceptor comprising a multi-compartment microfluidic device comprising an associated cell co-culture to which the sample is applied. The response of the neural network to the sample, in particular changes in the cell / neural network, is recorded and subsequently analyzed. And then differential diagnosis is carried out by comparing the network markers of the true positive and test samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of diagnostics, in particular to the field of diagnostic bioreceptors associated with microfluidics as biosensors. The present invention therefore relates to a method for determining the influence of a biological sample on a biological model, a bioreceptor implemented in such a method and the use of said bioreceptor. Background Art

[0002] Pathologies of the central and / or peripheral nervous system affect more than 700 million people worldwide, more than 10 million in Europe and tens of thousands in France. These pathologies are considered to be the most complex in terms of etiology, development and treatment. These neurocognitive disorders (e.g. Alzheimer's disease, Parkinson's disease, craniocerebral trauma, cerebrovascular accident or amyotrophic lateral sclerosis) cause cognitive, functional and / or behavioral deficits in the subject, i.e. alterations in abilities related to language, social interaction, memory, logical reasoning or autonomy. Therefore, these pathologies, also called neurological diseases or neurological disorders, constitute a major public health problem.

[0003] Currently, the diagnosis of these diseases is essentially made after the appearance and observation of the first symptoms. After the initial clinical diagnosis, the analysis of biological fluids such as blood or cerebrospinal fluid (CSF) is performed, supplemented by imaging tests. With regard to other neurological conditions, such as craniocerebral trauma (or concussion), the diagnosis is based on the establishment of the Glasgow score, which is established through clinical observation and symptoms.

[0004] In recent years, the existence of novel biomarkers has been demonstrated that allow the diagnosis of these neurological diseases or neurological disorders. For example, microRNAs present in biological fluids such as LCS or blood allow the diagnosis of concussions through very conventional bioassay techniques such as polymerase chain amplification (or polymerase chain reaction or PCR) or immunoenzymatic techniques on solid supports (or enzyme-linked immunosorbent assay or ELISA).

[0005] Current treatment is performed in the context of secondary and tertiary concomitant and preventive approaches, which aim to maintain quality of life, prevent complications and behavioral episodes by anticipating the advanced stage of the disease. Moreover, the complexity of establishing a reliable differential diagnosis makes the search for new treatments difficult. In fact, there may be identical or similar clinical symptoms for several different injuries, such as neurodegenerative diseases, because these conditions involve the same malfunctioning proteins.

[0006] Therefore, in order to ensure effective and earliest management of the disease, it is necessary to establish a reliable and early diagnosis of such neurological diseases or neurological disorders, thereby enabling improved determination of appropriate treatment.

[0007] However, to date, there are no sensitive, rapid and reproducible tests that allow for early and definitive diagnosis of cognitive, functional and / or behavioral deficits associated with neurological and / or neurological diseases.

[0008] Meanwhile, methods for determining the activity of agents (such as drugs) on neural activity are usually based on behavioral changes in living animals or the use of tissue biosensors. However, this type of behavioral testing in animal models is costly, time-consuming, difficult to quantify, and almost impossible to repeat.

[0009] The use of tissue-based biosensors overcomes some of the limitations imposed by behavioral testing and provides results that are more easily quantified. However, the sensitivity of such biosensors is limited and cannot detect subtle changes in cognitive function. Tissue biosensors that can detect agents that change or otherwise modify neural function are usually composed of cultured neurons maintained on an electrode network that records the passive properties of the cell membrane, such as input impedance or spontaneous action potential activity. Due to low sensitivity, these types of biosensors are mainly used to determine acute cell death caused by exposure to high concentrations of toxic agents (e.g., excitotoxicity induced by high concentrations of glutamate in synaptic grooves). In addition, most biosensors only provide short-term data.

[0010] In general, conventional solutions have the following disadvantages: / ) they do not allow or hardly allow the detection of the presence of unknown or new agents that may be at the origin of neurological diseases and / or neurological disorders or indicative of the presence of neurological diseases and / or neurological disorders; / ) they mainly detect the effects of fast-acting agents, while agents that take hours or days to produce an effect are generally not detectable by known methods; and / / / ) they cannot distinguish between affected neural clusters.

[0011] Based on the above, there is a clear need to develop new solutions that allow for a fast, effective, early and reliable differential diagnosis of neurological disorders and / or neurological diseases. Summary of the invention

[0012] The inventors have unexpectedly and surprisingly developed a method for determining the effect of a biological sample on a biological model involving a neural network. The method is implemented by an innovative biosensor, which includes, in particular, a bioreceptor, which advantageously includes the form of a multi-compartment microfluidic device. The method, including the bioreceptor for determining the effect of a biological sample on a biological model and its use, are described throughout this specification.

[0013] The purpose of the present invention is to obtain data on the state of a neural network exposed to a biological sample and then to analyze these data in order to establish a differential diagnosis of a neurological disease and / or a neurological disease in a subject quickly and at a lower cost, with an improved specificity / sensitivity ratio. In short, the purpose is to provide a treatment adapted to the subject, aimed at maintaining the quality of life, preventing complications and predicting the development of a pathology, in particular towards an advanced stage of the pathology.

[0014] Therefore, the present invention relates to an in vitro or ex vivo method for determining the effect of a biological sample on a biological model, comprising the following steps:

[0015] a. Providing a bioreceptor, the bioreceptor advantageously comprising a multi-compartment microfluidic device in the form of a multi-compartment microfluidic device comprising:

[0016] i) at least a first compartment and a second compartment;

[0017] ii) at least one device forming a biological interface for enabling communication via a neural connection between the first compartment and the second compartment;

[0018] iii) each compartment cultures at least one type of cell or explant, the first compartment at least comprising a neuronal culture in the form of a neural network, and the second compartment at least comprising a neuronal culture in the form of a neural network and / or a non-neuronal cell culture or explant culture;

[0019] iv) at least one device for recording the functional activity of neurons at a plurality of spatially distributed measurement points in the first compartment;

[0020] b. directly or indirectly contacting the neurons and / or non-neuronal cells or explants cultured in the second compartment with the biological sample;

[0021] c. recording the functional activity of the neurons cultured in the first compartment at a plurality of measurement points during the measurement duration after the contact according to step b);

[0022] d. converting the functional activity records of the neurons cultured in the first compartment into functional activity data;

[0023] e. analyzing the functional activity data obtained in step d);

[0024] f. determining at least one characteristic parameter of the state of the neural network in the first compartment by the functional activity data;

[0025] g. Comparing at least one characteristic parameter of the neural network state with a reference value of at least one characteristic parameter of the neural network state to determine the influence of the biological sample.

[0026] In the remainder of this disclosure, for simplicity:

[0027] - The term "neuron" is used equivalent to "nerve cell";

[0028] - the terms "neurological and / or neurological damage" are used synonymously with "central and / or peripheral nervous system pathology" or "neurocognitive damage" or "cognitive, functional and / or behavioral deficits"; and

[0029] - The term "injury" is used synonymously with "pathology", "attainment" or "damage".

[0030] In the context of the present invention, a "biological model" is understood as a culture of non-human, human cells derived from primary pluripotent or human stem cells, neurons or non-neuronal structures separated from their natural biological environment, either alone or in co-culture in a multi-compartment microfluidic structure, wherein the compartments are directly or indirectly connected. In other words, this includes culturing cells in an artificial environment with minimal changes to natural or in vivo conditions.

[0031] In the context of the present invention, a "biointerface" is understood to be a system comprising contact connections between cell populations contained in the device of the present invention, enabling communication of cells by exchanging information through electrical and / or chemical communication. Within the meaning of the present invention, this may consist of a culture of neuronal cells, non-neuronal cells or tissue explants.

[0032] In the context of the present invention, a "bioreceptor" is understood to be a group of molecules and / or cells that can selectively recognize a molecule (or analyte). For example, an enzyme, a cell, an aptamer, a nanoparticle or an antibody may be mentioned. Within the meaning of the present invention, a bioreceptor is a culture of neurons, such as human neurons derived from pluripotent stem cells, contained in a multi-compartment microfluidic device that models a network structure that may be a feature of a neurological pathology and / or neuropathology. The bioreceptor is associated with a converter that converts the connection between the analyte and the bioreceptor into a measurable signal. According to the present invention, the combination of the bioreceptor and the converter is defined as a biosensor, which has the advantage of establishing a fast and reliable diagnosis, particularly due to the presence of a biological interface in these microfluidic structures, which makes the bioreceptor more physiological, that is, it consists of an innovative experimental model whose physical, biochemical and biological organization, operation and reaction allow the results obtained to be transferred to humans. In the context of the present invention, a "biosensor" is understood to be a device comprising at least one bioreceptor as defined above and a device for converting the functional activity of neurons into functional activity data as described hereinafter.

[0033] In the context of the present invention, "functional activity of neurons" is understood to mean the emission and propagation of neural information in the form of electrical signals and / or neurotransmitter secretions.

[0034] In the context of the present invention, "means for converting the functional activity of neurons into functional activity data" should be understood as transducers. Sensors can be divided into three major categories: optical (such as optical fiber), electrochemical (such as current, potential, impedance or conductance) and mass-based (such as piezoelectric and magnetoelastic) transducers.

[0035] In the context of the present invention, a "node", "node connection" or "vertex / edge" is understood to be a collection of neurons, cell assemblies or neuron clusters that are connected in a continuous manner and have functional activity. It should be noted that the brain includes about 100 billion neurons and 1 neuron can establish up to 10,000 connections.

[0036] In the context of the present invention, a "module" is understood to be a plurality of nodes connected together to form a group or "cluster".

[0037] In the context of the present invention, an "action potential" or "spike" is understood as the occurrence of a neural influx, ie a succession of a brief and local depolarization of the plasma membrane followed by a repolarization of the inner membrane (possibly followed by hyperpolarization in unmyelinated cells).

[0038] In the context of the present invention, a "burst" is understood to be several action potentials within a given time period. A burst is usually defined as at least four action potentials in succession within a specified time period (e.g., 100 ms). For such a duration, a burst usually contains 10 to 100,000 spikes.

[0039] In the context of the present invention, a "network burst" is understood to be a group of action potentials that form a network, ie occur according to a defined synchronization. In other words, a network burst is detected by synchronized action potentials of several electrodes.

[0040] Preferably, the present invention relates to an in vitro or ex vivo method for determining the effect of a biological sample on a biological model, as described above, which has the following technical features considered alone or in combination:

[0041] - at least one characteristic parameter of the state of the neural network in the first compartment is selected from the group consisting of: the number of action potentials, the interval between action potentials or "ISI", the coefficient of variation of the interval between action potentials, the number of active electrodes, the average rate of normalized action potentials, the number of bursts, the number of electrodes that have captured one or several bursts, the average duration of bursts, the average value of action potentials in a burst (ISI), the average value of the interval between action potentials in a burst, the inter-burst interval or "IBI", the frequency of bursts, the percentage of bursts, the number of network bursts, the network burst frequency, the network burst duration, the average value of action potentials in a network burst, the average value of the interval between action potentials (ISI) in a network burst, the number of electrodes participating in forming a network burst, the percentage of bursts in a network burst, the coefficient of variation of the inter-burst interval (IBI) in a network burst, the surface area under the cross-correlation curve and the synchronization index,

[0042] - at least one characteristic parameter of the state of the neural network in the first compartment is selected from the group consisting of:

[0043] i) connection coefficient;

[0044] ii) the average value of the minimum length between nodes;

[0045] iii) the average value of action potentials per second;

[0046] iv) Network connectivity index or “small world index”;

[0047] v) z score or "z-score";

[0048] vi) participation factor or “participation factor”; and

[0049] vii) the centrality index of the node,

[0050] - The biointerface comprises, advantageously consists of, at least one element selected from the following group: a fluid microchannel; a PDMS microchannel; a porous membrane, the porosity of which is advantageously comprised between 10 nm and 40 μm and the pore density of which is advantageously comprised between 10 and 1.10 9 Holes / cm 2 between 1.10 and 1.10 5 to 1.10 9 Holes / cm 2between; porous capillary membranes, advantageously consisting of a membrane on which at least one organoid is cultured (i.e., a three-dimensional multicellular structure reproducing the microanatomical structure of an organ in vitro), said membrane being made of polycarbonate, polyester, polyethylene terephthalate and / or polytetrafluoroethylene; gels; hydrogels and mixtures thereof;

[0051] - constructing a graph representing the neural network of step e), the graph being obtained by implementing graph theory; advantageously, the nodes of the graph correspond to the measurement points of the functional activity and the connections between the nodes correspond to the correlations of the axonal communication;

[0052] - Step f) comprises determining from the functional activity data two parameters, advantageously three parameters, four parameters, preferably five parameters, six parameters or even seven characteristic parameters of the state of the neural network in the first compartment, said parameters being selected from the group consisting of:

[0053] i) connection coefficient;

[0054] ii) the average value of the minimum length between nodes;

[0055] iii) the average value of action potentials per second;

[0056] iv) Network connectivity index or “small-world index”;

[0057] v) z score or "z-score";

[0058] vi) participation factor or “participation factor”; and

[0059] vii) the centrality index of the node;

[0060] - The connectivity index of a network is the ratio between the connectivity coefficient and the average value of the minimum length between nodes;

[0061] The average value of action potentials per second should be greater than or equal to 0.5, advantageously strictly greater than 0.5, preferably 1 or 1.5, or even 2, in order to be able to analyze at least one parameter selected from the group consisting of:

[0062] i) connection coefficient;

[0063] ii) the average value of the minimum length between nodes;

[0064] iv) Network connectivity index or “small-world index”;

[0065] v) z score or "z-score";

[0066] vi) participation factor or “participation factor”; and

[0067] vii) the centrality index of the node;

[0068] - the value of the connection coefficient is greater than or equal to 0, preferably 0.5, advantageously comprised between 0 and 1;

[0069] -The average value of the minimum length between nodes is greater than or equal to 1, preferably 1.5 or 2;

[0070] - the value of the connectivity index of the network between nodes is greater than or equal to 0, preferably 0.5, advantageously comprised between 0 and 1;

[0071] - a value of the z score or "z-score" greater than or equal to 0, preferably 5, advantageously comprised between 0 and 10;

[0072] - the value of the participation coefficient or "participation coefficient" is greater than or equal to 0, preferably 0.5, advantageously comprised between 0.5 and 1;

[0073] - the value of the centrality index of the node is greater than or equal to 0, preferably 5, advantageously comprised between 6 and 10;

[0074] - a device allowing recording the functional activity of neurons at a plurality of measuring points spatially distributed in the first compartment, preferably in the first compartment and in at least one additional compartment, advantageously in all compartments, according to step a.iv), the device being a device capable of recording in indirect contact with the cultured cells, selected from the group consisting of:

[0075] - Devices for recording activity by planar or non-planar microelectrode arrays, semi-solid electrodes, amperometry or voltammetry;

[0076] - Fluorescence imaging recording devices, such as calcium imaging or transmembrane ion flow imaging; and

[0077] - Devices for recording intracellular, extracellular or patch clamp electrophysiological activity in whole-cell, attached-cell, inside-out or outside-out configurations;

[0078] - step d) of converting the functional activity record of the neurons cultured in the first compartment into functional activity data is performed by means of a device for converting the functional activity of the neurons into functional activity data, which device is an algorithmic system for converting electrical and / or electrophysiological data into binary data;

[0079] - the duration of the measurement of the functional activity recording of the neurons cultured in the first compartment according to step c) is between 300 ms and 20 min, advantageously between 1 min and 15 min, preferably between 5 min and 12 min;

[0080] - the multi-compartment microfluidic device further comprises a third compartment and at least one device forming a biological interface to enable communication via a neural connection between the first compartment and the third compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the second compartment and the third compartment; advantageously, a fourth compartment and at least one device forming a biological interface to enable communication via a neural connection between the first compartment and the fourth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the second compartment and the fourth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the third compartment and the fourth compartment; preferably, a fifth compartment and at least one device forming a biological interface to enable communication via a neural connection between the first compartment and the fifth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the second compartment and the fifth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the third compartment and the fifth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the fourth compartment and the fifth compartment;

[0081] - the contacting according to step b) is indirect, since the biological sample is applied to the biological interface of the second compartment and / or to at least one biological interface of the third compartment and / or to at least one biological interface of the fourth compartment and / or to at least one biological interface of the fifth compartment;

[0082] - Each compartment comprised in the device of the invention contains a culture of one, two or even three types of neurons and / or non-neuronal cells;

[0083] - the neuron is selected from the group consisting of glutamatergic neurons, GABAergic neurons, serotonergic neurons, cholinergic neurons, dopaminergic neurons, adrenergic neurons, noradrenergic neurons, sensory neurons and motor neurons;

[0084] - non-neuronal cells selected from the group consisting of glial cells (including microglia / macrophages and macroglia (i.e., oligodendrocytes, Schwann cells and ependymal cells)), epithelial cells, conjunctive cells, thyroid cells, adipocytes, blood cells, immune cells, bone cells, chondrocytes, gastric cells, pancreatic cells, liver cells, intestinal cells or lung cells, endothelial cells, muscle cells, vascular cells, cardiac cells, mesenchymal cells, retinal pigment epithelial cells and retinal cells;

[0085] - the explant is brain tissue, epithelial tissue, eye tissue, thyroid tissue, adipose tissue, vascular tissue, bone tissue, cartilage tissue, gastric tissue, pancreatic tissue, liver tissue, intestinal tissue, lung tissue, endothelial tissue, muscle tissue and tissue of retinal origin, cardiac tissue and placental tissue; and / or

[0086] - the biological sample is selected from the group consisting of: blood, saliva, urine, tears, sweat, sputum, mucus, pus, lymph, cerebrospinal fluid, nasopharyngeal secretions, oropharyngeal secretions, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, aqueous humor, amniotic fluid and plasma; and / or

[0087] -The biological sample can be an "agent" or "detection agent", i.e. a compound having neuronal functional activity modulating properties or an agent for which we do not know whether it has neuronal functional activity modulating properties, in which case the method of the invention allows the identification and / or characterization of the possible properties of the agent, and even the identification of a "threshold concentration". In other words, in particular when the detection agent is a drug, this is the concentration of the agent under the minimum treatment regimen (i.e. for a pharmaceutical composition, at the lowest therapeutic dose usually prescribed for an animal or a human). In an embodiment of the invention, the comparison with the reference value carried out in step g) comprises comparing at least one characteristic parameter of the state of the neural network of the invention consisting of a value obtained before the administration of the agent or detection agent with a value obtained after the administration of the agent or detection agent, said value being earlier in time to ensure monitoring of the effect of the agent or detection agent.

[0088] Therefore, in the context of the present invention:

[0089] - "number of action potentials" is understood as the number of action potentials detected during the recording (detection parameter defined upstream of the recording);

[0090] - “Inter-action potential interval” or “ISI”, to be understood as the average duration between detected action potentials;

[0091] - "Coefficient of variation of the action potential interval" should be understood as the standard deviation of the ISI divided by the mean ISI. This parameter is related to the regularity of the action potential and reflects its distribution;

[0092] - "number of active electrodes" is understood as the number of active electrodes having a minimum average rate of action potentials greater than or equal to the minimum average rate of action potentials defined before recording,

[0093] - "Average rate of normalized action potentials" should be understood as the number of action potentials divided by the recording time (average value). This parameter is usually defined in Hz or spikes / s (action potentials / second). This parameter is determined only from the functional activity data measured on the active electrodes defined before recording;

[0094] - "number of bursts" is understood to mean the number of bursts recorded per electrode or the total number (sum of bursts of all electrodes),

[0095] - "Number of electrodes that have captured bursts" is understood to be the total number of electrodes for which the number of bursts / minute has been measured. This number of bursts / minute can be defined before recording. For example, this may include at least 5 bursts / minute;

[0096] - “mean duration of the burst” is understood to mean the mean time between the first and the last action potential of each measured burst;

[0097] - "mean value of action potentials in a burst" or "mean value of spikes in a burst" is to be understood as the average number of action potentials in a measured burst;

[0098] - "mean value of the inter-action potential interval (ISI) in a burst" is to be understood as the mean value of the intervals between action potentials defined in a burst;

[0099] - "Inter-burst interval" or "IBI", which is understood to be the average duration between different recorded bursts;

[0100] - "burst frequency" is understood as the total number of bursts divided by the recording time. This parameter is usually defined in Hz or bursts / min;

[0101] - "percentage of bursts" is understood as the ratio between the number of action potentials in a burst and the total number of action potentials recorded;

[0102] - “number of network bursts” is understood to mean the total number of network bursts identified during the recording process;

[0103] - "Network burst frequency" is understood to be the total number of network bursts divided by the recording time. This parameter is usually defined in Hertz;

[0104] - “network burst duration” should be understood as the average time between two action potentials in a network burst;

[0105] - “mean value of action potentials in the burst network” should be understood as the mean value of action potentials detected in all recorded burst networks;

[0106] - "mean value of the inter-action potential interval (ISI) in the network bursts" is to be understood as the mean value of the ISIs defined in all recorded network bursts;

[0107] - “the number of electrodes participating in forming a network burst” is understood to mean the average number of active electrodes in a network burst;

[0108] - “percentage of bursts in network bursts” is understood as the ratio between the number of action potentials in network bursts and the total number of action potentials recorded;

[0109] - "coefficient of variation of the inter-burst interval (IBl) in network bursts" shall be understood as the standard deviation of the IBI divided by the mean value of the IBI;

[0110] - "surface area under the cross-correlation curve" is understood to be the surface area under the cross-correlation curve between electrodes. This parameter can be determined according to the method defined in Halliday, Rosenber, Breeze and Conway in their publication "Neural Spike Train Synchronization Indices: Definitions, Interpretations, and Applications" in 2006;

[0111] - "Synchrony index", which should be understood as a measure of synchronization comprised between 0 and 1 (without units). This parameter can be determined according to the publication "A comparison of binless spike train measures" (Paiva et al., 2010);

[0112] - "Connectivity coefficient" or "clustering coefficient", which should be understood as the probability that two nodes are connected given that they have common neighbors;

[0113] - "average value of the minimum length between nodes" shall be understood as the average value of the length between two connected nodes; and

[0114] - "mean value of action potentials per second" is to be understood as the mean value of the number of neural influxes per second, i.e. a succession of brief and local depolarization of the plasma membrane followed by repolarization of the inner membrane (possibly followed by hyperpolarization in unmyelinated cells);

[0115] - "Connectivity index of the network" or "small-world index", which is understood as the structural (physical, i.e. synapses and axons) and physiological (functional / symmetric and effective / causal) connectivity between two or more nodes, which is a reflection of the robustness of the neural network. Preferably, the connectivity index of the network is determined by the ratio between the connectivity coefficient and the average value of the minimum length between nodes;

[0116] - z score or "z-score", which should be understood as a measure that allows characterizing how the connectivity of nodes is distributed in a module, that is, within-module characterization;

[0117] - participation coefficient or "participation coefficient", understood as a measure that allows characterizing how the connectivity of a node is distributed between several modules (ie inter-module); and

[0118] - "centrality index of a node" is understood to be a value proportional to the number of times this node is passed during a random process on a graph representing a neural network according to the invention, randomly along one of the links starting from the node.

[0119] These characteristic parameters of the state of the neural network in the first compartment determined from the recorded functional activity data can be used individually or in combination. They are divided into the following four categories:

[0120] 1 / Spike (action potential) analysis. This category includes the following parameters: number of action potentials, average number of action potentials per second, inter-action potential interval or "ISI", coefficient of variation of the inter-action potential interval, number of active electrodes, average rate of normalized action potentials;

[0121] 2 / Burst analysis. This category includes the following parameters: number of bursts, number of electrodes that have captured one or several bursts, average duration of the average action potential in a burst, average inter-action potential interval (ISI) in a burst, inter-burst interval or “IBI”, frequency of bursts and percentage of bursts.

[0122] 3 / Network burst analysis. This category includes the following parameters: number of network bursts, network burst frequency, network burst duration, mean value of action potentials in network bursts, mean value of inter-action potential intervals (ISI) in network bursts, number of electrodes involved in forming network bursts, percentage of bursts in network bursts, coefficient of variation of inter-burst intervals (IBI) in network bursts.

[0123] 4 / Network connectivity. This latter category applies to any type of network, including neural networks. It includes the following parameters, some of which are determined using the so-called cross-correlation connectivity algorithm (see “Total spiking probability edges: A cross-correlation based method for effective connectivity estimation of cortical spiking neurons” Deblasi et al., 2019): the surface area under the cross-correlation curve, the synchronization index, the connectivity coefficient, the average of the minimum lengths between nodes, the connectivity index or “small-world index” of the network, the participation coefficient or “participation coefficient” and the centrality index of the nodes.

[0124] In particular, the device allowing the functional activity of neurons to be recorded at a plurality of measurement points spatially distributed in the first compartment according to step a.iv) comprises electrodes in direct or indirect contact with the neurons. This device allows the recording of polarization differences of neurons that allow them to communicate with each other through action potentials characterized by a potential difference greater than 1 μV.

[0125] The device for converting functional activity into functional activity data according to step a.iv) of the present invention is an algorithm system for converting electrical and / or electrophysiological data into binary data. Specifically, this includes:

[0126] i) converting the electrophysiological data by means of a signal converter provided with a recording device, said converter being coupleable to a signal amplifier;

[0127] ii) establishing a detection threshold to binarize the electrophysiological activities of neurons in each node individually or collectively;

[0128] iii) creating a spatiotemporal matrix of the functional activity of the nodes based on the data obtained in the previous step, the so-called matrix data; and

[0129] iv) creating a graph representing the cross-temporal and weighted spatiotemporal correlation of the activity of each node connected to other nodes, in order to provide a set of quantitative data (or matrix data) in the configuration of pathological manifestations, which is proven to be characteristic of each biological model according to the present invention. In particular, this consists in generating a "functional activity signature" which will be compared with a "reference library of functional activity signatures" or "functional activity signatures of the same previously recorded network" or "a collection of functional activities of the same previously recorded network", thereby allowing the establishment of relative differences between the recorded signature and the reference signature.

[0130] In the context of the present invention, "functional activity signature" is understood as an activity characteristic, ie a possible change in the functional activity, ie the electrical activity, of the neurons in the culture in the form of a network in the first compartment of the device according to the invention.

[0131] In the context of the present invention, a "functionally active feature library" should be understood as a collection of different activity features of multiple biological samples (e.g., 2 or more, advantageously more than 10, preferably more than 100, more than 1000, or more than 10,000, or even more than 100,000 biological samples) that can be identified from each other.

[0132] In the context of the present invention, the comparison with the reference values ​​carried out in step g) consists in comparing at least one characteristic parameter of the state of the neural network of the present invention (in terms of seconds, minutes, hours, days, months and / or years) consisting of the values ​​obtained from the previously prepared sample with at least one characteristic parameter of the state of the neural network obtained after the administration of the sample, the effects of which were achieved by the method of the present invention; and / or at least one characteristic parameter consisting of values ​​originating from a reference library or reference set. In particular,

[0133] - in the case of an in vitro or ex vivo method for determining the influence of a biological sample on a biological model to ensure monitoring of the state of a subject (i.e. monitoring the upward or downward development of a pathology (in particular the development of a neurological disease and / or a neurological disease), the manifestation of a pathology (in particular the manifestation of a neurological disease and / or a neurological disease) or the effect of a treatment by administering an agent / detecting an agent), then, monitoring over time the value of at least one characteristic parameter of the state of a neural network with an evolution criterion (upper or lower threshold value, in particular with a standard deviation, using a derivative, during an analysis period advantageously comprised between 30 seconds and 60 minutes, advantageously between 1 minute and 50 minutes, between 2 minutes and 40 minutes, between 3 minutes and 30 minutes, even between 4 minutes and 20 minutes, preferably between 5 minutes and 10 minutes);

[0134] - In the case of a comparison of at least one characteristic parameter of the neural network state with an existing library of functional activities, all recorded parameters i) to vii) should be taken into account, which in particular allows to obtain a more reliable differential diagnosis, i.e. to distinguish between different possible diagnoses for which there may be identical or similar clinical symptoms, since these disorders involve the same dysfunctional protein. In this case, the comparison step according to the invention comprises, preferably consists of, an absolute comparison with other so-called "true positive" and / or "true negative" subjects, forming a group or "cluster" of reference subjects / data; or

[0135] - The comparison with a reference value performed in step f) may also comprise an absolute comparison with a library and monitoring of the subject's state as previously described.

[0136] For example, in the case of determining the presence or absence of SARS-CoV-2 or COVID-19 infection, step f) of the method of the invention comprises, advantageously consists of, an absolute comparison of the functional activity library.

[0137] For example, in the case of establishing a differential diagnosis of Alzheimer's disease and Parkinson's disease, step g) of the method of the invention consists of an absolute comparison of the functional activity repertoire, advantageously consisting of an absolute comparison of the functional activity repertoire. Afterwards, in order to monitor the development of the impairment, the value of the connectivity index (parameter iv) of the network is advantageously monitored over time with a progression criterion (upper or lower threshold in the average time period with standard deviation, using a derivative).

[0138] For example, in the case of determining the presence or absence of head trauma, step g) of the method of the invention comprises, advantageously consists of, monitoring the development of the injury by monitoring the value of the connectivity index (parameter iv) of the network over time with a progression criterion (upper or lower threshold in an average time period with a standard deviation, using a derivative).

[0139] For example, the means for converting the functional activity into functional activity data is an algorithmic system for converting electrical and / or electrophysiological data into binary data.

[0140] According to the present invention, it may include converting the functional activity signal recorded by the MEA2100-Headstage system (Multi-Channel Systems, Reutlingen, Germany) into a digital signal by an analog-to-digital converter, which may be coupled to an amplifier or amplifier group, and the converter is directly integrated into the recording device. The data stream binary signal is read by the software MEA2100-256-Systems (Multi-Channel Systems, Reutlingen, Germany) provided with the device. Alternatively, it may also include converting the functional activity signal recorded by the M768tMEA-16 (Axion Biosystems, Atlanta, Georgia, USA) system into a digital signal by an analog-to-digital converter, which may be coupled to an amplifier or amplifier group, and the converter is directly integrated into the recording device. The binary data stream signal is read by the Axis Navigator (Axion Biosystems, Atlanta, Georgia, USA) software provided with the device.

[0141] For example, the means of converting the digital activity of a node into a binary signal of the node is ensured by a thresholding algorithm well known to those skilled in the art, which consists in analyzing the background noise of the signal and applying suitable filters in order to apply a binarization threshold to the entire signal.

[0142] The method of the invention allows the application of a biological sample derived from a subject (e.g. a sample of cerebrospinal fluid, blood, salivary mucus or a test reagent) to a bioreceptor which advantageously comprises the form of a multi-compartment microfluidic device incorporating relevant cell co-cultures (neurons and / or non-neurons and / or explant cells). Preferably, the sample is applied indirectly to the neuronal culture, i.e., not on the neuronal culture, but on at least one relevant co-culture, which then acts via a biological interface connected to the neuronal culture, the neurons extending via axons and / or synapses, for example in the microchannels of the multi-compartment microfluidic device of the invention. Subsequently, the response of the neural network after the application of the biological sample, i.e. possible changes in the functional activity of the neural network, is recorded and analyzed.

[0143] Specifically, the change in the functional activity of the neural network can be carried out by any means known to those skilled in the art, in particular by:

[0144] - alterations in functional communication, i.e. changes in the efficiency of intercellular communication, in which the ability of one or several neurons to activate target neurons with which they are synaptically or non-synaptically connected is increased, decreased or destroyed;

[0145] - alteration of the axonal and / or dendritic connection network, for example by destruction of said axons and / or dendrites;

[0146] - alterations in one or a few cell types that impair neuronal communication, such as interference with glial cells only within the node, and / or

[0147] - Alteration of the action potential, i.e. increase or decrease in amplitude, frequency, duration, "threshold" potential, allowing membrane depolarization and / or rhythmic variation of the action potential.

[0148] These changes then lead to changes in at least one parameter selected from the group consisting of: i) connectivity coefficient; ii) mean value of minimum length between nodes; iii) mean value of action potentials per second; iv) network connectivity index; v) z-score; vi) participation coefficient; and vii) centrality index of nodes. A functional activity signature derived from the correlation of said parameters is thereby obtained, which is or is not characteristic of a pathological state. Finally, a diagnosis is performed by comparing the functional activity signature thus obtained with a so-called "true positive" functional activity signature, i.e., a network labeled as a true positive.

[0149] The results of implementing the method of the invention in differential diagnosis allow obtaining results by functional analysis of neural networks in less than 72 hours, advantageously in less than 48 hours, preferably in less than 24 hours, or in less than 12 hours, 6 hours, 3 hours, 2 hours, 1 hour, or in less than 30 minutes, 20 minutes, 15 minutes or less than 10 minutes or even immediately.

[0150] As can be seen from the above, the innovation of the present invention lies in the use of network markers as diagnostic markers, identifying relevant neural-cell-explant structures (i.e., neurons or non-neurons or tissue explant cells) to establish a given diagnosis, and quantifying the network markers by diagnostic type to confirm the diagnosis.

[0151] One of the advantages of the method of the invention is that it allows establishing a reliable differential diagnosis, i.e. a diagnosis that allows distinguishing a neurological pathology and / or a neuropathology from another pathology with close or similar symptoms or from a pathology with few or no observable symptoms during primary clinical auscultation.

[0152] Another advantage of the method of the present invention is that it ensures a rapid differential diagnosis.

[0153] In addition, the method of the invention allows to improve the specificity / sensitivity ratio. In fact, compared with the limits of conventional molecular coupling (such as ELISA) or PCR amplification, the method of the invention has a better detection resolution; due to the use of neurons and at least one related co-culture, it allows to model the specific cell and molecular structure used to diagnose a given pathology, ensuring specificity.

[0154] Furthermore, the method of the present invention is low-cost because it does not require the use of specific machines such as ELISA assays, immunospecific labeling, PCR or other biochemical assay techniques.

[0155] Finally, the method of the invention is less restrictive and, depending on the mode of sampling intervention, may be almost non-invasive, since it requires the use of very small fluid volumes, preferably in the microliter range, allowing for implementation in microfluidic devices.

[0156] The invention also relates to a bioreceptor and a biosensor comprising said bioreceptor, where appropriate, to determine the effect of a biological sample on a biological model. In particular, it consists of a bioreceptor capable of being implemented in the method of the invention as described above.

[0157] The present invention thus relates to a bioreceptor, and a biosensor comprising said bioreceptor, where appropriate for determining the effect of a biological sample on a biological model, the bioreceptor advantageously comprising the form of a multi-compartment microfluidic device comprising:

[0158] i) at least a first compartment and a second compartment;

[0159] ii) at least one device forming a biological interface to enable communication via a neural connection between the first compartment and the second compartment ( Figure 1 );

[0160] iii) each compartment cultures at least one type of cell or explant, the first compartment contains at least a neuronal culture in the form of a neural network, the second compartment contains at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture or explant culture, and the biological sample can be applied to the second compartment;

[0161] iv) at least one device capable of recording the functional activity of neurons at a plurality of measurement points spatially distributed in the first compartment, which device may be combined with a device for converting the functional activity into data.

[0162] Preferably, the present invention relates to a bioreceptor, and a biosensor comprising the bioreceptor where appropriate, for determining the effect of a biological sample on a biological model as described above, having the following technical features alone or in combination:

[0163] - The biointerface comprises, advantageously consists of, at least one element selected from the following group: a fluid microchannel; a PDMS microchannel; a porous membrane, the porosity of which is advantageously comprised between 10 nm and 40 μm and the pore density of which is advantageously comprised between 10 and 1.10 9 Holes / cm 2 between 1.10 and 1.10 5 to 1.10 9 Holes / cm 2 between; porous capillary membranes, advantageously consisting of a membrane on which at least one organoid is cultured (i.e., a three-dimensional multicellular structure reproducing the microanatomical structure of an organ in vitro), said membrane being made of polycarbonate, polyester, polyethylene terephthalate and / or polytetrafluoroethylene; gels; hydrogels and mixtures thereof;

[0164] - it also includes a device for converting the functional activity record of the neurons cultured in the first compartment into functional activity data;

[0165] - it further comprises analysis means arranged to determine from the functional activity data at least one characteristic parameter of the state of the neural network in the first compartment, said at least one parameter being selected from the group consisting of:

[0166] i) connection coefficient;

[0167] ii) the average value of the minimum length between nodes;

[0168] iii) the average number of action potentials per second; and

[0169] iv) Network connectivity index or “small world index”;

[0170] v) z score or "z-score";

[0171] vi) participation factor or “participation coefficient”;

[0172] vii) the centrality index of the node;

[0173] - it further comprises analysis means arranged to determine from the functional activity data at least one characteristic parameter of the state of the neural network in the first compartment, said at least one parameter being selected from the group consisting of: the number of action potentials, the inter-action potential interval or "ISI", the coefficient of variation of the inter-action potential interval, the number of active electrodes, the average rate of normalized action potentials, the number of bursts, the number of electrodes that have captured one or several bursts, the average duration of bursts, the average value of action potentials in a burst, the average value of the inter-action potential interval (ISI) in a burst, the inter-burst interval or "IBI", the frequency of bursts, the percentage of bursts, the number of network bursts, the network burst frequency, the network burst duration, the average value of action potentials in a network burst, the average value of the inter-action potential interval (ISI) in a network burst, the number of electrodes involved in forming a network burst, the percentage of bursts in a network burst, the coefficient of variation of the inter-burst interval (IBI) in a network burst, the surface area under the cross-correlation curve and the synchronization index;

[0174] - it also comprises means for making a comparison between at least one characteristic parameter of the state of the neural network and a reference value of at least one characteristic parameter of the state of the neural network to determine the influence of the biological sample;

[0175] - the multi-compartment microfluidic device further comprises a third compartment and at least one means for forming a biological interface to enable communication via a neural connection between the first compartment and the third compartment (1, 3) and / or at least one means for forming a biological interface to enable communication via a neural connection between the second compartment and the third compartment ( Figure 2 ); Advantageously, the fourth compartment and at least one device forming a biological interface to enable communication via a neural connection between the first compartment and the fourth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the second compartment and the fourth compartment and / or at least one device forming a biological interface to enable communication via a neural connection between the third compartment and the fourth compartment ( Figure 3); preferably, the fifth compartment and at least one device forming a biological interface to achieve communication through a neural connection between the first compartment and the fifth compartment and / or at least one device forming a biological interface to achieve communication through a neural connection between the second compartment and the fifth compartment and / or at least one device forming a biological interface to achieve communication through a neural connection between the third compartment and the fifth compartment and / or at least one device forming a biological interface to achieve communication through a neural connection between the fourth compartment and the fifth compartment ( Figure 4 );

[0176] - It may be included in a portable or non-portable kit and is intended to determine the effects of biological samples on biological models, ultimately establishing a differential diagnosis of neurological diseases and / or neurological disorders.

[0177] The present invention also relates to the use of the aforementioned bioreceptors and biosensors comprising the same in an in vitro or ex vivo method for diagnosing neurological diseases or neurological diseases, which are advantageously selected from the group consisting of: Alzheimer's disease; Parkinson's disease; head trauma; cerebrovascular accident, thrombotic or embolic occlusion or ischemia; transient ischemic attack; neuronal forms of SARS-CoV-2 infection; neuronal poisoning, for example poisoning by organophosphorus compounds; analgesia; neuroinflammatory diseases, such as multiple sclerosis, otitis media, myelitis, lupus, Crohn's disease; hearing loss caused by damage to the auditory nerve; amyotrophic lateral sclerosis; retinal neuropathy, for example caused by diabetes; epilepsy, psoriasis, herpes; meningoencephalitis; isolated lymphocytic meningitis; Guillain-Barré syndrome or mononeuritis type polyradiculoneuritis; peripheral neuropathy and myelopathy.

[0178] The present invention also relates to the use of the aforementioned bioreceptors and biosensors comprising said bioreceptors in an in vitro or ex vivo method for monitoring a neurological disease or a preventive and / or therapeutic treatment of a neurological disease, advantageously by gene therapy, cell therapy, axonal regeneration therapy, administration of one or more therapeutic and / or preventive and / or anesthetic agents.

[0179] The present invention further relates to the aforementioned bioreceptor and the biosensor comprising the bioreceptor for use in the method for quickly and sensitively screening a reagent or detection reagent as a potential drug. In fact, the device of the present invention allows the identification of the possible therapeutic effect of the detection reagent, and the physiologically relevant concentration (e.g., the amount present in a specific tissue when the prescribed dose) of the reagent identified as a drug is assessed. The detection reagent is indirectly applied to the neuron culture in the first compartment to produce a recognizable or characteristic functional activity signal, thereby allowing the therapeutic effect of the reagent to be assessed quickly and effectively. With reference to the accompanying drawings, the present invention is illustrated in a non-limiting manner by the following embodiments.

[0180] It is believed that, given the description and embodiments, one skilled in the art should be able to make and use the claimed methods and bioreceptors without further explanation.

[0181] The invention also relates to an in vitro or ex vivo method for determining the effect of a biological sample on a biological model, comprising the following steps:

[0182] a. Providing a bioreceptor comprising a multi-compartment microfluidic device (10), the device comprising:

[0183] i) at least a first compartment (1) and a second compartment (2);

[0184] ii) at least one device forming a biological interface (21) for enabling communication via a neural connection between the first compartment and the second compartment;

[0185] iii) each compartment cultures at least one type of cell or explant, the first compartment (1) contains at least a neuronal culture in the form of a neural network, and the second compartment (2) to which the biological sample can be applied contains at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture or explant culture;

[0186] iv) at least one device (40) capable of recording the functional activity of neurons at a plurality of measurement points spatially distributed in the first compartment, which device can be combined with a device (50) for converting the functional activity into data;

[0187] b. directly or indirectly contacting the neurons cultured in the first compartment or the neurons and / or non-neuronal cells or explants cultured in the second compartment with the biological sample;

[0188] c. recording the functional activity of the neurons cultured in the first compartment (1) at a plurality of measurement points during the measurement duration after the neurons cultured in the first compartment (1) are contacted with the biological sample according to step b);

[0189] d. converting the functional activity records of the neurons cultured in the first compartment (1) into functional activity data;

[0190] e. analyzing the functional activity data obtained in step d) and constructing a graph representing a neural network;

[0191] f. Determining at least one characteristic parameter of the state of the neural network in the first compartment (1) from the functional activity data, the at least one parameter being selected from the group consisting of:

[0192] i) connection coefficient;

[0193] ii) the average value of the minimum length between nodes;

[0194] iii) the average value of action potentials per second;

[0195] iv) Network connectivity index or “small-world index”;

[0196] v) z score or "z-score";

[0197] vi) participation factor or “participation factor”; and

[0198] vii) the centrality index of the node;

[0199] g. Comparing at least one characteristic parameter of the neural network state with a reference value of at least one characteristic parameter of the neural network state to determine the influence of the biological sample. BRIEF DESCRIPTION OF THE DRAWINGS

[0200] [ Figure 1 ]: A diagram showing a bioreceptor of the present invention in the form of a microfluidic device comprising two compartments.

[0201] [ Figure 2 ]: Diagram showing a bioreceptor of the present invention in the form of a microfluidic device comprising three compartments.

[0202] [ Figure 3 ]: A diagram showing a bioreceptor of the present invention in the form of a microfluidic device comprising four compartments.

[0203] [ Figure 4 ]: A diagram showing a bioreceptor of the present invention in the form of a microfluidic device comprising 5 compartments.

[0204] [ Figure 5 ]: A diagram showing the different elements required to implement the method of the present invention.

[0205] [ Figure 6 ]: A diagram showing the implementation steps of the method according to the present invention.

[0206] [ Figure 7]: represents the implementation steps of the method according to the present invention for healthy subjects and subjects with neurological diseases and / or neurological diseases and the data obtained from each of these steps. DETAILED DESCRIPTION

[0207] As mentioned earlier, in Figure 1 and 5 In the first embodiment shown, the present invention relates to a bioreceptor comprising a multi-compartment microfluidic device, wherein in the first embodiment, the device comprises a first compartment 1 and a second compartment 2, each compartment comprising a culture of at least one type of cells or explants; and at least one device forming a biological interface 21 to enable communication through neuronal connections between the first compartment 1 and the second compartment 2.

[0208] The bioreceptor of the invention further comprises at least one device 40 allowing recording the functional activity of neurons at a plurality of measurement points spatially distributed in the first compartment, said device being combinable with a device 50 for converting the functional activity into functional activity data, a device 60 for analyzing these functional activity data, which is arranged to determine from the functional activity data at least one characteristic parameter of the state of the neural network in the first compartment, and a device 70 for comparing at least one characteristic parameter of the state of the neural network with a reference value of at least one characteristic parameter of the state of the neural network in order to determine the influence of the biological sample.

[0209] The at least one parameter may be selected from the group consisting of:

[0210] i) connection coefficient;

[0211] ii) the average value of the minimum length between nodes;

[0212] iii) the average number of action potentials per second; and

[0213] iv) Network connectivity index or “small world index”;

[0214] v) z score or "z-score";

[0215] vi) participation factor or “participation coefficient”;

[0216] vii) Centrality index of the node.

[0217] The at least one parameter may also be selected from the group consisting of: the number of action potentials, the interval between action potentials or "ISI", the coefficient of variation of the interval between action potentials, the number of active electrodes, the average rate of normalized action potentials, the number of bursts, the number of electrodes that have captured one or several bursts, the average duration of bursts, the average value of action potentials in bursts, the average value of the interval between action potentials (ISI) in bursts, the inter-burst interval or "IBI", the frequency of bursts, the percentage of bursts, the number of network bursts, the frequency of network bursts, the duration of network bursts, the average value of action potentials in network bursts, the average value of the interval between action potentials (ISI) in network bursts, the number of electrodes involved in forming network bursts, the percentage of bursts in network bursts, the coefficient of variation of the inter-burst interval (IBI) in network bursts, the surface area under the cross-correlation curve, and the synchronization index.

[0218] When two or more parameters are used to characterize the state of the neural network in the first compartment from the functional activity data, this may include a combination of parameters belonging to the same group, or a combination of parameters each from one of the two groups.

[0219] exist Figure 2 In the second embodiment shown, the bioreceptor of the present invention also includes a third compartment 3; at least one device 31 forming a biological interface to achieve communication through neuronal connections between the first compartment 1 and the third compartment 3, and / or at least one device 32 forming a biological interface to achieve communication through neuronal connections between the second compartment 2 and the third compartment 3.

[0220] exist Figure 3 In the third embodiment represented, the bioreceptor of the present invention also includes a fourth compartment 4; at least one device 41 forming a biological interface to achieve communication through neuronal connections between the first compartment 1 and the fourth compartment 4, and / or at least one device 42 forming a biological interface to achieve communication through neuronal connections between the second compartment 2 and the fourth compartment 4, and / or at least one device 43 forming a biological interface to achieve communication through neuronal connections between the third compartment 3 and the fourth compartment 4.

[0221] exist Figure 4In the fourth embodiment represented, the bioreceptor of the present invention also includes a fifth compartment 5; at least one device 51 for forming a biological interface to achieve communication through neuronal connections between the first compartment 1 and the fifth compartment 5, and / or at least one device 52 for forming a biological interface to achieve communication through neuronal connections between the second compartment 2 and the fifth compartment 5, and / or at least one device 53 for forming a biological interface to achieve communication through neuronal connections between the third compartment 3 and the fifth compartment 5, and / or at least one device 54 for forming a biological interface to achieve communication through neuronal connections between the fourth compartment 4 and the fifth compartment 5.

[0222] like Figure 6 and 7 (including sub Figure 7 7A, 7B', 7C', 7A, 7B and 7C), the implementation of the in vitro or ex vivo method for determining the influence of a biological sample on a biological model according to the present invention allows obtaining a record of the functional activity of neurons cultured in the first compartment 1 ( Figure 7 A' and 7A), i.e., the recording of the extracellular activity of neurons reflected by the peaks of the so-called "spikes", which occur periodically when the neural network is synchronized (or under non-pathological conditions). Therefore, a strong activity of the neural network cultured in the first compartment 1 is observed by the appearance of bursts of peaks of the so-called "bursts". In contrast, other types of neurons, such as GABAergic neurons, do not present a synchronized functional activity (data not shown). In this case, a possible disturbance of the functional activity will not lead to a desynchronization of the "spikes" and / or a reduction or absence of the "bursts", nor will it change the characteristic parameters of the neural network state according to the invention.

[0223] The recording of the functional activity of the neurons in the form of a network cultured in the first compartment is subjected to a conversion device 50 which allows obtaining functional activity data, in particular binary data ( Figure 7 B' and 7B).

[0224] These functional activity data are in turn submitted to the analysis means 60, which are arranged to determine from the functional activity data at least one characteristic parameter of the state of the neural network in the first compartment, the at least one parameter being selected from the group consisting of:

[0225] i) connection coefficient;

[0226] ii) the average value of the minimum length between nodes;

[0227] iii) the average number of action potentials per second; and

[0228] iv) Network connectivity index or “small world index”;

[0229] v) z score or "z-score";

[0230] vi) participation factor or “participation coefficient”;

[0231] vii) Centrality index of the node.

[0232] In summary, these characteristic data / parameters of the neural network state are related and can be represented in the form of a cross-correlation graph ( Figure 7 C' and 7C).

[0233] The bioreceptor comprises means 70 for comparing at least one characteristic parameter of the neural network state with a reference value of at least one characteristic parameter of the neural network state to determine the effect of administration of the biological sample on the biological model and thereby determine the presence or absence of a neurological disease and / or a neurological disease in the subject, or to determine a new treatment regimen (new molecule or new dosimetry) from screening of the detection agent.

[0234] In particular, when the average value of action potentials per second is higher than 0.5, it is possible to analyze at least one parameter selected from the group consisting of:

[0235] i) connection coefficient;

[0236] ii) the average of the minimum lengths between nodes; and

[0237] iv) Network connectivity index or “small-world index”;

[0238] v) z score or "z-score";

[0239] vi) participation factor or “participation coefficient”;

[0240] vii) the centrality index of the node;

[0241] In particular, the analysis advantageously consists in determining the value of the ratio of the average connection coefficients to the minimum lengths between nodes, ultimately allowing the determination of a connectivity index for the network, which index will be the parameter implemented in the comparison step.

[0242] Implementation

[0243] The present invention will be further described in connection with a bioreceptor comprising a multi-compartment microfluidic device 10 comprising 2 compartments (Examples 1 to 3) or 5 compartments (Example 4). Nevertheless, these examples do not limit the present invention in any way.

[0244] Example 1: Diagnosis of Alzheimer's disease

[0245] 1. Background

[0246] In Europe, more than 10 million people suffer from neurodegenerative diseases such as Alzheimer's disease (AD), and this number tends to double in less than 20 years. There is no curative treatment for these conditions, and the complexity of establishing a reliable differential diagnosis makes it difficult to find new treatments. The first damage of AD appears in the hippocampus, which is an area of ​​the brain involved in memory processes (recording, retrieval and organization of memory) and emotional management, and then the damage gradually spreads to the direction of external areas as connections are established between different brain regions. The hippocampus is a structure composed of glial cells (astrocytes or microglia) and neurons, most of which are glutamatergic neurons and GABAergic neurons.

[0247] 2. Equipment and Methods

[0248] The bioreceptor of the present invention is in the form of a multi-compartment device, wherein a first compartment contains a culture of human glutamatergic neurons derived from stem cells and a second compartment contains a culture of human GABAergic neurons derived from stem cells.

[0249] The glutamatergic neurons are stored in nitrogen at a temperature of about -200°C. The gradual thawing steps are carried out according to conventional techniques known to those skilled in the art. The thawed cells are then placed in about 10 mL of a dedicated culture medium at 37°C. The sample is centrifuged and then processed using an automatic counter or a Malassez cell to determine the concentration of glutamatergic neurons and the dilution to be performed. Afterwards, the sample is diluted and inoculated in the first compartment of the device according to the invention, which has been pre-treated according to conventional techniques known to those skilled in the art to promote the adhesion of glutamatergic neurons to the substrate.

[0250] GABAergic neurons were cultured in the second compartment of the device according to the same protocol as detailed above.

[0251] The functional activity of the glutamatergic neurons thus cultured was recorded by a planar microelectrode array (MEA) 256MEA100 / 30iR-ITO-w / o (Multichannel Systems, Reutlingen, Germany), which consists of electrodes of 30 μm diameter separated by electrodes of 100 μm. This recording was performed for 10 min with the aid of MEA2100-256-Systems software (Multichannel Systems, Reutlingen, Germany). The microelectrode array technology allows recording the functional and spontaneous extracellular activity of neurons as a marker of network connectivity.

[0252] For functional logging, two conditions have been tested:

[0253] - "Test" condition: CSF samples from subjects who may have MA; and

[0254] - "Reference" condition: CSF sample from a so-called "true negative" subject that serves as a reference value.

[0255] In particular, with regard to the "reference" condition, it should be noted that it consists of samples obtained from healthy subjects and presenting a negative result in conventional AD tests. In other words, it consists of samples reflecting a so-called "true negative" diagnosis.

[0256] 3. Results

[0257] Results from Figure 7 A', 7B', 7C', 7A, 7B and 7C represent.

[0258] During electrophysiological recordings, cultured glutamatergic neurons showed functional activities represented by dots ( Figure 7 A' and 7A). These peaks are detected in time and space by the software algorithm MEA2100-256-Systems, which then assigns a value determined by each point on the peak.

[0259] Based on the values ​​identified by the algorithm, a matrix (grid map or grid plot) is generated in order to visualize the activity of each active electrode as a function of time ( Figure 7 B' and 7B). This graph allows the assessment of the synchrony of the neural network, i.e. the ability of neurons to be active at the same time. From these graphs it is clear that the glutamatergic neural network is synchronized under "reference" conditions ( Figure 7 B'), while in the "test" condition it is asynchronous ( Figure 7 B).

[0260] Furthermore, the optimal structure of the network is defined by quantitative parameters obtained through a cross-correlation algorithm and allows the quality of the network connectivity to be assessed. In this case, the average value of the action potentials per second is above 0.5; this allows the determination of the value of the ratio of the average connectivity coefficient to the minimum length between nodes and, ultimately, the value of the connectivity index of the network.

[0261] As mentioned before, the processing and analysis of the data obtained allow the representation of a neural network defined by a node and its interaction with another node ( Figure 7 C' and 7C). Cross-correlation is an algorithm that represents the degree of a neural network and allows the evaluation of the state function of the network.

[0262] Analysis of the network showed that the neural network under the "test" condition ( Figure 7 C) than the neural network under the "reference" condition ( Figure 7 C') has fewer connections.

[0263] 4. in conclusion

[0264] As can be seen from the practice of the methods of the present invention, the samples of the "test" conditions are obtained from subjects suffering from neurological diseases and / or neurological disorders.

[0265] Representation of the neural network under the "test" condition ( Figure 7 C) Comparison with a library of functional activity signatures allows for the establishment of a rapid and reliable Alzheimer's disease diagnosis.

[0266] Afterwards, the subject's status is monitored (i.e. monitoring the upward or downward progression of AD) by monitoring the value of the network connectivity index (parameter iv) over time with a progression criterion (upper or lower threshold in the average time period, with standard deviation, using the derivative) relative to a reference value corresponding to the value obtained at the time of disease diagnosis (i.e. the value obtained as described previously).

[0267] Example 2: Diagnosis of head trauma in a rugby match

[0268] 1. Background

[0269] In some dangerous sports, such as rugby, athletes are at high risk of head trauma (or concussion). It can be defined as a short-term dysfunction of brain function in the absence of macroscopic or microscopic injury. The frequency of concussions has been increasing over the past 15 years. In rugby, the incidence ranges from 4.1 to 7.9 per athlete per 1,000 hours of play. Currently, diagnosis is based on the Glasgow score established based on clinical observations and symptoms. Concussions can be caused by impacts other than to the head, and the athlete's clinical signs and symptoms may be very mild or even unnoticed, but there is no loss of cognition, which can make diagnosis more difficult and slow. The time between diagnosis and prognosis for athletes can be very long and can keep athletes out of action for days or weeks, sometimes with harmful, severe and long-term consequences.

[0270] 2. Equipment and Methods

[0271] The bioreceptor of the present invention is in the form of a multi-compartment device, wherein the first compartment contains a culture of human sensory neurons derived from stem cells and the second compartment contains a culture of oral mucosal cells. See the protocol detailed in point 2 of Example 1.

[0272] For functional logging, two conditions have been tested:

[0273] - "Test" condition: saliva samples obtained from subjects who experienced impact during a rugby match; and

[0274] - "Reference" condition: saliva samples obtained from healthy subjects that showed negative results for conventional tests for detecting head trauma. In other words, it consisted of samples reporting so-called "true negative" diagnoses.

[0275] 3. Results

[0276] The data were obtained according to the protocol detailed in point 3 of Example 1.

[0277] 4. Conclusion

[0278] As can be seen from the practice of the methods of the present invention, the samples of the "test" conditions are obtained from subjects suffering from neurological diseases and / or neurological disorders.

[0279] Comparison of the representation of the neural network under the "test" condition with the library of functional activity signatures allows establishing a rapid and reliable diagnosis of the presence of head trauma, thus ensuring rapid and effective management of the subject.

[0280] Example 3: Diagnosis of COVID-19 disease

[0281] 1. Background

[0282] Coronaviruses are known to cause severe acute respiratory syndrome. Three deadly epidemics have occurred in the 21st century. SARS-CoV-2, which causes the disease COVID-19, is the source of the most recent pandemic, with extremely high mortality and economic losses. In Europe, the cumulative mortality rate is 34%, and it varies from country to country, which is related to the emergence of new variants of SARS-CoV-2 and the strong heterogeneity of symptoms (asymptomatic persons, benign forms, individual deaths). The ability of coronaviruses to invade the central nervous system has been described in two previous epidemics caused by SARS-CoV-1 and MERS-CoV. The severity of the described neurological symptoms varies from simple headaches and temporary confusion to the most severe cerebrovascular accidents and convulsions. As with many other viral diseases transmitted through the air, infections of the upper respiratory tract are the first entry point into the human body. This is even more so because olfactory attacks after SARS-CoV-2 infection, including the loss of smell detection (anosmia), remain one of the most common and predictive symptoms of infection even with current tests. In particular, it has been indicated that neuroinvasion occurs via the nasal route. In fact, it has been demonstrated that intact virus particles are present in the supporting cells of the olfactory mucosa, which means that this place could be the site of viral replication, which incidentally explains the loss of taste and smell. The hypothesis regarding neural invasion is that viral transmission occurs through the olfactory bulb (site of olfactory sensory information processing) and then invades the central nervous system through cranial nerves.

[0283] 2. Equipment and Methods

[0284] The bioreceptor of the present invention is in the form of a multi-compartment device, wherein the first compartment contains a culture of human mitral valve cells from the olfactory bulb and the second compartment contains a culture of nasal mucosal cells. See the protocol detailed in point 2 of Example 1.

[0285] Regarding the functional record, two conditions have been tested:

[0286] - "Test" condition: nasopharyngeal samples obtained from subjects;

[0287] - "Reference" condition: Nasopharyngeal samples obtained from healthy subjects and with negative results for conventional tests for detecting COVID-19 disease. In other words, it consists of samples that reflect a so-called "true negative" diagnosis.

[0288] 3. Results

[0289] The data were obtained according to the protocol detailed in point 3 of Example 1.

[0290] 4. in conclusion

[0291] As can be seen from the practice of the methods of the present invention, the samples of the "test" conditions are obtained from subjects suffering from neurological diseases and / or neurological disorders.

[0292] Comparison of the representation of the neural network under the "test" condition with a library of functional activity signatures allows establishing a rapid and reliable diagnosis of the pathogenic condition of the COVID-19 disease.

[0293] Example 4: Diagnosis of Parkinson's disease

[0294] 1. Background

[0295] Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, with a prevalence of 4% in people over 80 years old. From a clinical point of view, it has motor symptoms, affecting walking and body movements, and is associated with non-motor symptoms. Dementia is a common symptom of Parkinson's disease, corresponding to Parkinson's dementia or Lewy body dementia.

[0296] From a neuropathological point of view, PD is characterized by the loss of dopaminergic neurons in the substantia nigra (SN), an anatomical region belonging to the basal ganglia, and the presence of intracellular inclusions called Lewy bodies. α-Synuclein is located in these Lewy bodies and, when poorly folded and formed, leads to a neurotoxic cascade.

[0297] The axonal projections of the SN extend to the putamen and caudate nucleus (forming the striatum), where there are series of connections to the globus pallidus and subthalamic nucleus. In PD, degeneration of the nigrostriatal pathway (the pathway between the substantia nigra and striatum) is the primary cause of motor symptoms. A key consequence of the death of dopaminergic neurons and the reduction of dopamine in the SN is the disturbance of dopaminergic signaling from the basal ganglia to the rest of the brain. The motor circuit of the basal ganglia controls movement. Within this circuit, a direct pathway and an indirect pathway are found. The direct pathway consists of 5 anatomical areas: the cortex, striatum, substantia nigra pars compacta, thalamus, and connections between the globus pallidus internalis and substantia nigra reticulata.

[0298] 2. Equipment and Methods

[0299] The bioreceptor of the present invention is in the form of a multi-compartment device, wherein the first compartment contains a culture of human glutamatergic and GABAergic cells derived from pluripotent stem cells, the second compartment contains a culture of GABAergic neurons, the third compartment contains a culture of glutamatergic neurons, the fourth compartment contains a culture of GABAergic neurons, and the fifth compartment contains dopaminergic neurons. These five compartments correspond to the five anatomical regions of the basal lymph node ring. See the scheme detailed in point 2 of Example 1.

[0300] For functional logging, two conditions have been tested:

[0301] - "Test" condition: CSF samples from subjects with possible Parkinson's disease; and

[0302] - "Reference" condition: CSF sample from a so-called "true negative" subject that serves as a reference value.

[0303] In particular, with regard to the "reference" condition, it should be noted that it consists of samples obtained from healthy subjects and presenting a negative result in a conventional Parkinson's disease test. In other words, it consists of samples reflecting a so-called "true negative" diagnosis.

[0304] 3. Results

[0305] The data were obtained according to the protocol detailed in point 3 of Example 1.

[0306] 4. in conclusion

[0307] As can be seen from the practice of the methods of the present invention, the samples of the "test" conditions are obtained from subjects suffering from neurological diseases and / or neurological disorders.

[0308] Comparison of the representation of the neural network under the "test" condition with the library of functional activity signatures allows establishing a rapid and reliable diagnosis of the pathogenic condition of Parkinson's disease.

Claims

1. An in vitro or ex vivo method for determining the effect of a biological sample on a biological model, The following steps are involved: a. Providing a bioreceptor comprising a multi-compartment microfluidic device (10), the device comprising: i) at least a first compartment (1) and a second compartment (2); ii) at least one device forming a biological interface (21) for enabling communication via a neural connection between said first compartment and said second compartment; iii) the first compartment (1) contains at least a neuronal culture in the form of a neural network, and the second compartment (2) contains at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture or explant culture; iv) at least one device (40) for recording the functional activity of neurons at a plurality of spatially distributed measurement points in said first compartment; b. directly or indirectly contacting the neurons and / or non-neuronal cells or explants cultured in the second compartment with the biological sample; c. recording the functional activity of the neurons cultured in the first compartment (1) at a plurality of measuring points during the measurement duration after the contact according to step b); d. converting the functional activity records of the neurons cultured in the first compartment (1) into functional activity data; e. analyzing the functional activity data obtained in step d); f. determining at least one characteristic parameter of the state of the neural network in the first compartment (1) from the functional activity data; g. Comparing at least one characteristic parameter of the neural network state with a reference value of at least one characteristic parameter of the neural network state to determine the influence of the biological sample.

2. The method according to claim 1, It is characterized in that At least one characteristic parameter of the state of the neural network in the first compartment (1) is selected from the group consisting of: the number of action potentials, the interval between action potentials or "ISI", the coefficient of variation of the interval between action potentials, the number of active electrodes, the average rate of normalized action potentials, the number of bursts, the number of electrodes that have captured one or several bursts, the average duration of bursts, the average value of action potentials in bursts, the average value of the interval between action potentials (ISI) in bursts, the inter-burst interval or "IBI", the frequency of bursts, the percentage of bursts, the number of network bursts, the network burst frequency, the network burst duration, the average value of action potentials in network bursts, the average value of the interval between action potentials (ISI) in network bursts, the number of electrodes involved in forming network bursts, the percentage of bursts in network bursts, the coefficient of variation of the inter-burst interval (IBI) in network bursts, the surface area under the cross-correlation curve and the synchronization index.

3. The method according to claim 1 or 2, It is characterized in that At least one characteristic parameter of the state of the neural network in the first compartment (1) is selected from the group consisting of: i) connection coefficient; ii) the average value of the minimum length between nodes; iii) the average value of action potentials per second; iv) Network connectivity index or "small world index"; v) z score or "z-score"; vi) participation factor or "participation factor"; and vii) Centrality index of the node.

4. The method according to claim 3, It is characterized in that Step f) comprises determining from said functional activity data two parameters, advantageously three parameters, preferably four parameters, or even five parameters, in particular six parameters, more particularly seven characteristic parameters of the state of the neural network in said first compartment, said parameters being selected from the group consisting of: i) connection coefficient; ii) the average value of the minimum length between nodes; iii) the average value of action potentials per second; iv) Network connectivity index or "small world index"; v) z score or "z-score"; vi) participation factor or "participation factor"; and vii) Centrality index of the node.

5. The method according to claim 3 or 4, It is characterized in that Step g) comprises the step of comparing with a threshold value, namely: - comparing the average value of action potentials per second with a threshold value of the average value of action potentials per second, the value of the threshold value of the average value of action potentials per second being greater than or equal to 0.5, advantageously strictly greater than 0.5; and / or - comparing the connection coefficient with a connection coefficient threshold value, the value of which is greater than or equal to 0, advantageously comprised between 0 and 1; and / or - comparing the average value of the minimum lengths between nodes with a threshold value of the average value of the minimum lengths between nodes, the threshold value of the average value of the minimum lengths between nodes having a value greater than or equal to 1, advantageously greater than or equal to 1.5; and / or - comparing the connectivity index of the inter-node connectivity network with an inter-node connectivity threshold, the value of the inter-node connectivity threshold being greater than or equal to 0, advantageously comprised between 0 and 1; and / or - a z score or "z-score" value greater than or equal to 0, advantageously greater than or equal to 5 and preferably comprised between 0 and 10; and / or - the value of the participation coefficient or "participation coefficient" is greater than or equal to 0, advantageously greater than or equal to 0.5 and preferably comprised between 0.5 and 1; and / or The value of the centrality index of the node is greater than or equal to 0, advantageously greater than or equal to 5, preferably comprised between 6 and 10.

6. The method according to any one of the preceding claims, It is characterized in that Step g) comprises comparing at least one characteristic parameter of the neural network state defined by step f) with a reference library of functional activity signatures.

7. The method according to any one of claims 3 to 6, It is characterized in that Step g) comprises monitoring the value of parameter iv) using an upward or downward progression criterion during the analysis period.

8. The method according to any one of claims 3 to 7, It is characterized in that When the average value of the action potentials per second is higher than 0.5, determination of at least one characteristic parameter of the neural network state selected from the group consisting of: i) connection coefficient; ii) the average value of the minimum length between nodes; iii) Network connectivity index or "small world index"; iv) z score or "z-score"; v) participation factor or "participation factor"; and vi) Centrality index of the node.

9. The method according to claim 8, It is characterized in that Determining at least one characteristic parameter of the state of the neural network advantageously comprises determining a connectivity index of the network, said connectivity index consisting of the value of the ratio of the connection coefficient to the minimum length between nodes.

10. The method according to any one of the preceding claims, It is characterized in that The means (40) allowing recording the functional activity of neurons at a plurality of spatially distributed measurement points in said first compartment (1) according to step a.iv) is a means (40) for recording in indirect contact with cultured cells, which is selected from the group consisting of: - Devices for recording activity by planar or non-planar microelectrode arrays, semi-solid electrodes, amperometry or voltammetry; - Fluorescence imaging recording devices, such as calcium imaging or transmembrane ion flow imaging; and - Devices for recording intracellular, extracellular or patch clamp electrophysiological activity in whole-cell, attached-cell, inside-out or outside-out configurations.

11. The method according to any one of the preceding claims, It is characterized in that Step d) of converting the functional activity record of neurons cultured in the first compartment (1) into functional activity data is carried out by a device (50) for converting the functional activity of neurons into functional activity data, and the conversion device (50) is preferably an algorithm system for converting electrical and / or electrophysiological data into binary data.

12. The method according to any one of the preceding claims, It is characterized in that The measurement duration of the recording of the functional activity of the neurons cultured in the first compartment according to step c) is between 300 ms and 20 min, advantageously between 1 min and 15 min, preferably between 5 min and 12 min.

13. The method according to any one of the preceding claims, It is characterized in that The multi-compartment microfluidic device (10) further comprises: i) a third compartment (3) comprising at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture; and ii) at least one device (31) forming a biological interface to enable communication via a neural connection between the first compartment and the third compartment (1, 3), and / or at least one device (32) forming a biological interface to enable communication via a neural connection between the second compartment and the third compartment (2, 3).

14. The method according to claim 13, It is characterized in that The multi-compartment microfluidic device (10) further comprises: iii) a fourth compartment (4) comprising at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture; and iv) at least one device (41) forming a biological interface to enable communication via a neural connection between the first compartment and the fourth compartment (1, 4), and / or at least one device (42) forming a biological interface to enable communication via a neural connection between the second compartment and the fourth compartment (2, 4), and / or at least one device (43) forming a biological interface to enable communication via a neural connection between the third compartment and the fourth compartment (3, 4).

15. The method according to claim 14, It is characterized in that The multi-compartment microfluidic device (10) further comprises: v) a fifth compartment (5) comprising at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture; and vi) at least one device (51) forming a biological interface to enable communication through a neural connection between the first compartment and the fifth compartment (1, 5), and / or at least one device (52) forming a biological interface to enable communication through a neural connection between the second compartment and the fifth compartment (2, 5), and / or at least one device (53) forming a biological interface to enable communication through a neural connection between the third compartment and the fifth compartment (3, 5), and / or at least one device (54) forming a biological interface to enable communication through a neural connection between the fourth compartment and the fifth compartment (4, 5).

16. The method according to any one of the preceding claims, It is characterized in that The contact according to step b) is indirect because the biological sample is applied to the biological interface of the second compartment (21) and / or at least one biological interface of the third compartment (31, 32) and / or at least one biological interface of the fourth compartment (41, 42, 43) and / or at least one biological interface of the fifth compartment (51, 52, 53, 54).

17. A method according to any one of the preceding claims, Features: - the neuron is selected from the group consisting of: glutamatergic neurons, GABAergic neurons, serotonergic neurons, cholinergic neurons, dopaminergic neurons, adrenergic neurons, noradrenergic neurons, sensory neurons and motor neurons; and / or - the non-neuronal cells are selected from the group consisting of glial cells, epithelial cells, conjunctival cells, thyroid cells, adipocytes, blood cells, immune cells, bone cells, chondrocytes, stomach cells, pancreatic cells, liver cells, intestinal cells, lung cells, endothelial cells, muscle cells, vascular cells, cardiac cells, mesenchymal cells, retinal pigment epithelial cells, retinal pigment epithelial cells and retinal cells; and / or - The explant is brain tissue, epithelial tissue, eye tissue, thyroid tissue, adipose tissue, vascular tissue, bone tissue, cartilage tissue, stomach tissue, pancreatic tissue, liver tissue, intestinal tissue, lung tissue, endothelial tissue, muscle tissue, retinal tissue, heart tissue and placenta-derived tissue.

18. A method according to any one of the preceding claims, It is characterized in that The biological sample is selected from the group consisting of blood, saliva, urine, tears, sweat, sputum, mucus, pus, lymph, cerebrospinal fluid, nasopharyngeal secretions, oropharyngeal secretions, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, aqueous humor, amniotic fluid and plasma.

19. The method according to any one of claims 1 to 17, It is characterized in that The biological sample is a reagent or a detection reagent.

20. A biosensor for determining the effect of a biological sample on a biological model, comprising a multi-compartment microfluidic device (10), the device include: i) at least a first compartment (1) and a second compartment (2); ii) at least one means (21) forming a biological interface to enable communication via a neural connection between the first compartment and the second compartment (1, 2); iii) the first compartment (1) comprises at least a neuronal culture in the form of a neural network, to which the biological sample can be applied; the second compartment (2) comprises at least a neuronal culture in the form of a neural network and / or a non-neuronal cell culture or explant culture; iv) at least one device (40) capable of recording the functional activity of neurons at a plurality of measurement points spatially distributed in said first compartment.

21. A biosensor comprising the bioreceptor according to claim 20, It is characterized in that It also includes means for converting the functional activity record of the neurons cultured in the first compartment into functional activity data.

22. The biosensor according to claim 21, It is characterized in that It also comprises an analysis device (60) arranged to determine from the functional activity data at least one characteristic parameter of the state of the neural network in the first compartment, the at least one parameter being selected from the group consisting of: i) connection coefficient; ii) the average value of the minimum length between nodes; iii) the average value of action potentials per second; iv) Network connectivity index or "small world index"; v) z score or "z-score"; vi) participation factor or "participation factor"; and vii) Centrality index of the node.

23. The biosensor according to claim 21, It is characterized in that It also includes an analysis device (60), which is configured to determine at least one characteristic parameter of the state of the neural network in the first compartment from the functional activity data, the at least one parameter being selected from the group consisting of: the number of action potentials, the interval between action potentials or "ISI", the coefficient of variation of the interval between action potentials, the number of active electrodes, the average rate of normalized action potentials, the number of bursts, the number of electrodes that have captured one or more bursts, the average duration of bursts, the average value of action potentials in bursts, the average value of the interval between action potentials (ISI) in bursts, the inter-burst interval or "IBI", the frequency of bursts, the percentage of bursts, the number of network bursts, the network burst frequency, the network burst duration, the average value of action potentials in network bursts, the average value of the interval between action potentials (ISI) in network bursts, the number of electrodes involved in forming network bursts, the percentage of bursts in network bursts, the coefficient of variation of the interval between bursts (IBI) in network bursts, the surface area under the cross-correlation curve and the synchronization index.

24. The biosensor according to claim 22 or 23, Features Also included is a device (70) for comparing at least one characteristic parameter of the neural network state with a reference value of at least one characteristic parameter of the neural network state to determine the influence of the biological sample.

25. Use of a bioreceptor according to claim 20 or a biosensor according to any one of claims 21 to 24 in an in vitro or ex vivo method for diagnosing neurological diseases and / or neurological diseases, which are advantageously selected from the group consisting of: Alzheimer's disease; Parkinson's disease; head trauma; cerebrovascular accident, thrombotic or embolic occlusion or ischemia; transient ischemic attack; neuronal form of SARS-CoV-2 infection (= covid-19); neuronal poisoning, for example poisoning by organophosphorus compounds; analgesia; neuroinflammatory diseases, such as multiple sclerosis, otoneuritis, myelitis, lupus, Crohn's disease; hearing loss due to auditory nerve damage; amyotrophic lateral sclerosis; retinal neuropathy, for example caused by diabetes; epilepsy, psoriasis, herpes; meningoencephalitis; isolated lymphocytic meningitis; Guillain-Barré syndrome or monoradiculoneuritis polyradiculoneuritis; peripheral neuropathy and myelopathy.

26. Use of a bioreceptor according to claim 20 or a biosensor according to any one of claims 21 to 24 in an in vitro or ex vivo method for monitoring a neurological disease or a preventive and / or therapeutic treatment of a neurological disease, advantageously said treatment being by gene therapy, cell therapy, axonal regeneration therapy, administration of one or more therapeutic and / or preventive and / or anesthetic agents.

27. Use of a bioreceptor according to claim 20 or a biosensor according to any one of claims 21 to 24 in an in vitro or ex vivo method for identifying and / or characterizing the therapeutic properties of an agent and / or the threshold concentration of an agent.